Yan M.-J.,No. 210 Hospital of PLA |
Chen R.-L.,Dalian Medical University |
Piao F.-Y.,Dalian Medical University
Journal of Dalian Medical University | Year: 2014
Objective: To investigate apoptotic effect of 2,5 - Hexanedione (2,5 - HD) on bone marrow mesenchymal stem cells (BMSCs) of rats and its mechanism.Methods: Thecellswere isolated from Bone marrows of rats and cultured. The morphology ofcells were observed, their surface markers were determined by flow cytomerty. Moreover, the cells could be induced tofat cells andosteoblasts. These cells were confirmed to be BMSCs. In this study, the fifth generation of rat BMSCs was exposed to 0, 10, 20 and 40 mmol/L 2,5 - HD for 24 h and the cells viability was measured by MTT assay. Themorphological changes of BMSCs were observed using HE staining and The apoptotic morphologic changes of BMSCs were observed by Hoechst 33342 staining. The protein expression of Bcl - 2 and Baxwasdetermined by Western blot.Results: Our results showed thatexposure to 2,5 - HD decreased survival of BMSCs and induced apoptosis. Moreover, 2,5 - HD significantly increasedBaxexpression (P < 0.05) and significantly decreased Bel - 2 expression (P < 0.05).Conclusion: These results suggest that 2,5-HD - induced apoptosis of BMSCs may be associated withdisturbanceinBax/Bcl - 2 protein expression.
Jin H.-T.,Peoples Liberation Army 202 Hospital |
Piao F.-Y.,Dalian Medical University |
Guan H.,No. 210 Hospital of PLA |
Li S.-Y.,Dalian Medical University
Journal of Dalian Medical University | Year: 2015
Objective: To observe the effect of acrylamide on the neurobehavioral and neurophysiology of rats. Methods: Thirty rats were randomly and evenly divided into 3 groups: control group, low - and high - dose group. The rats in 3 groups were injected intraperitoneally with normal saline, 20 mg/kg and 40 mg/kg acrylamide respectively for 10 weeks (3 d/w). The general state, gait and weight changes of the rats were observed, and nerve conduction velocity and distal latency were detected. Results: Compared with the control group, the weight of rats exposed to acrylamide decreased progressively with prolonged exposure. After 8 weeks, there was weight loss in the rats of high - dose group. In rats of low - and high - dose group, abnormal gait were found on 8 w and 4 w respectively and the gait scores were 2.00 ±0.00 and 4.00 ± 0.00 respectively at 10 weeks. From the 3rd week, distal latency increased and nerve conduction velocity decreased significantly. Compared with the control group, nerve conduction velocity were increased by 15.13% and 33.06%, and distal latency decreased by 17.41% and 58. 75% in the low - and high - dose groups (P < 0. 05). Conclusion: The chronic exposure to acrylamide would cause the abnormal changes of neurobehavioral and neurophysiological in rats, then lead to peripheral neuropathy.
Gao G.-Q.,General Hospital of Beijing Military Command |
Ma Q.-Y.,General Hospital of Beijing Military Command |
Guan H.,No. 210 Hospital of PLA |
Shang L.-X.,General Hospital of Beijing Military Command
Journal of Dalian Medical University | Year: 2015
Objective: To survey the incidence of premature rupture of membrane (PROM) in a large sample of pregnant women to provide a basis for further understanding the disease and its clinical treatment. Methods: We enrolled 2544 pregnant women in the study and conducted a retrospective analysis. Demographic characteristics were investigated. Potential risk factors were analyzed. Results: (1) In 2544 pregnant women, 392 patients had PROM with an incidence rate of 15.4%. (2) Mothers with lower education and urinary and reproductive system infection, exposed to passive smoking, complicated with diabetes mellitus and taking vitamin compound preparations for relatively long time during pregnancy had significantly higher incidence of PROM (P <0. 05). (3) Incidence of PROM increased with maternal age and times of abortion (P<0. 05). Conclusions: Some demographic characteristics, repeated abortion history and some adverse events during pregnancy are associated with risk of PROM. The relationship between intake of vitamin compound preparations and PROM is worth to be studied further.
Guan H.,General Hospital of Beijing Military Command |
Li S.,Dalian Medical University |
Guo Y.,Dalian Medical University |
Liu X.,No. 210 Hospital of PLA |
And 5 more authors.
International Journal of Molecular Sciences | Year: 2016
We previously reported that arsenic (As) impaired learning and memory by down-regulating calmodulin-dependent protein kinase IV (CaMK IV) in mouse cerebellum. It has been documented that the thyroid hormone receptor (TR)/retinoid X receptor (RXR) heterodimer and thyroid hormone (TH) may be involved in the regulation of CaMK IV. To investigate whether As affects the TR/RXR heterodimer and TH, we determined As concentration in serum and cerebellum, 3,5,3’-triiodothyronine (T3) and thyroxin (T4) levels in serum, and expression of CaMK IV, TR and RXR in cerebellum of mice exposed to As. Cognition function was examined by the step-down passive avoidance task and Morris water maze (MWM) tests. Morphology of the cerebellum was observed by Hematoxylin-Eosin staining under light microscope. Our results showed that the concentrations of As in the serum and cerebellum of mice both increased with increasing As-exposure level. A significant positive correlation was found between the two processes. A deficit in learning and memory was found in the exposed mice. Abnormal morphologic changes of Purkinje cells were observed in cerebellum of the exposed mice. Moreover, the cerebellar expressions of CaMK IV protein and the TRβ gene, and TRβ1 protein were significantly lower in As-exposed mice than those in controls. Subchronic exposure to As appears to increase its level in serum and cerebella of mice, impairing learning and memory and down-regulating expression of TRβ1 as well as down-stream CaMK IV. It is also suggested that the increased As may be responsible for down-regulation of TRβ1 and CaMK IV in cerebellum and that the down-regulated TRβ1 may be involved in As-induced impairment of learning and memory via inhibiting CaMK IV and its down-stream pathway. © 2016 by the authors; licensee MDPI, Basel, Switzerland.
Han Y.,General Hospital of Shenyang Military Command |
Guo J.,Capital Medical University |
Zheng Y.,Jilin University |
Zang H.,No. 463 Hospital of PLA |
And 20 more authors.
JAMA - Journal of the American Medical Association | Year: 2015
Importance: The safety and efficacy of bivalirudin compared with heparin with or without glycoprotein IIb/IIIa inhibitors in patients with acutemyocardial infarction (AMI) undergoing primary percutaneous coronary intervention (PCI) are uncertain. OBJECTIVE To determine if bivalirudin is superior to heparin alone and to heparin plus tirofiban during primary PCI. Design, Setting, and Participants: Multicenter, open-label trial involving 2194 patients with AMI undergoing primary PCI at 82 centers in China between August 2012 and June 2013. Interventions: Patients were randomly assigned to receive bivalirudin with a post-PCI infusion (n = 735), heparin alone (n = 729), or heparin plus tirofiban with a post-PCI infusion (n = 730). Among patients treated with bivalirudin, a postprocedure 1.75mg/kg/h infusion was administered for a median of 180 minutes (IQR, 148-240 minutes). Main outcomes and Measures: The primary end pointwas 30-day net adverse clinical events, a composite of major adverse cardiac or cerebral events (all-cause death, reinfarction, ischemia-driven target vessel revascularization, or stroke) or bleeding. Additional prespecified safety end points included the rates of acquired thrombocytopenia at 30 days, and stent thrombosis at 30 days and 1 year. Results: Net adverse clinical events at 30 days occurred in 65 patients (8.8%) of 735 who were treated with bivalirudin compared with 96 patients (13.2%) of 729 treated with heparin (relative risk [RR], 0.67; 95%CI, 0.50-0.90; difference, -4.3%, 95%CI, -7.5%to -1.1%; P = .008); and 124 patients (17.0%) of 730 treated with heparin plus tirofiban (RR for bivalirudin vs heparin plus tirofiban, 0.52; 95%CI, 0.39-0.69; difference, -8.1%, 95%CI, -11.6%to -4.7%; P < .001). The 30-day bleeding rate was 4.1%for bivalirudin, 7.5%for heparin, and 12.3%for heparin plus tirofiban (P < .001). There were no statistically significant differences between treatments in the 30-day rates of major adverse cardiac or cerebral events (5.0%for bivalirudin, 5.8% for heparin, and 4.9% for heparin plus tirofiban, P = .74), stent thrombosis (0.6%vs 0.9%vs 0.7%, respectively, P = .77), acquired thrombocytopenia (0.1%vs 0.7%vs 1.1%; P = .07), or in acute (<24-hour) stent thrombosis (0.3%in each group). At the 1-year follow-up, the results remained similar. Conclusions and Relevance: Among patients with AMI undergoing primary PCI, the use of bivalirudin with a median 3-hour postprocedure PCI-dose infusion resulted in a decrease in net adverse clinical events compared with both heparin alone and heparin plus tirofiban. This finding was primarily due to a reduction in bleeding events with bivalirudin, without significant differences in major adverse cardiac or cerebral events or stent thrombosis.